| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Net Sales | 24,575.00 | 32,681.00 | 34,229.00 | 35,355.00 | 32,184.00 | 32,136.00 | 32,765.00 | 31,657.00 | 30,109.00 | 30,274.00 |
| Total Revenues | 24,575.00 | 32,681.00 | 34,229.00 | 35,355.00 | 32,184.00 | 32,136.00 | 32,765.00 | 31,657.00 | 30,109.00 | 30,274.00 |
| Cost of sales | 14,447.00 | 18,477.00 | 19,232.00 | 18,795.00 | 16,605.00 | 17,136.00 | 16,682.00 | 16,001.00 | 15,040.00 | 15,383.00 |
| Gross Profit | 10,128.00 | 14,204.00 | 14,997.00 | 16,560.00 | 15,579.00 | 15,000.00 | 16,083.00 | 15,656.00 | 15,069.00 | 14,891.00 |
| Goodwill impairment expense | -- | 0.00 | 271.00 | -- | -- | -- | -- | -- | -- | -- |
| Research, development and related expenses | 1,085.00 | 1,842.00 | 1,862.00 | 1,994.00 | 1,878.00 | 1,911.00 | 1,821.00 | 1,850.00 | 1,735.00 | 1,763.00 |
| Selling, general and administrative expenses | 4,221.00 | 21,526.00 | 9,049.00 | 7,197.00 | 6,929.00 | 7,029.00 | 7,602.00 | 6,572.00 | 6,111.00 | 6,182.00 |
| Other (expense) income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain on sale of pharmaceuticals business | -- | -- | -- | -- | 389.00 | 114.00 | 547.00 | 586.00 | -- | -- |
| Loss (Gain) on business divestitures | -- | 36.00 | 2,724.00 | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19,753.00 | 41,809.00 | 27,690.00 | 27,986.00 | 25,023.00 | 25,962.00 | 25,558.00 | 23,837.00 | 22,886.00 | 23,328.00 |
| Operating Income (Loss) | 4,822.00 | (9,128.00) | 6,539.00 | 7,369.00 | 7,161.00 | 6,174.00 | 7,207.00 | 7,820.00 | 7,223.00 | 6,946.00 |
| Interest expense | -- | -- | -- | -- | -- | -- | -- | -- | 199.00 | 149.00 |
| Interest income | -- | -- | -- | -- | -- | -- | -- | -- | 29.00 | 26.00 |
| Other expense (income), net | (3.00) | (560.00) | (147.00) | (165.00) | (450.00) | (462.00) | 207.00 | (272.00) | -- | -- |
| Pre-Tax Income: United States | 2,300.00 | (12,091.00) | 3,861.00 | 3,716.00 | 3,720.00 | 3,008.00 | 3,487.00 | -- | 4,366.00 | 4,399.00 |
| Pre-Tax Income - International | 2,519.00 | 2,403.00 | 2,531.00 | 3,488.00 | 2,991.00 | 2,704.00 | 3,513.00 | -- | 2,687.00 | 2,424.00 |
| Income before income taxes, minority interest and cumulative effect of accounting | 4,819.00 | (9,688.00) | 6,392.00 | 7,204.00 | 6,711.00 | 5,712.00 | 7,000.00 | 7,548.00 | 7,053.00 | 6,823.00 |
| Current : Federal | (75.00) | 376.00 | 606.00 | 756.00 | 720.00 | 534.00 | 698.00 | -- | 1,192.00 | 1,338.00 |
| Current : State | (6.00) | 78.00 | 606.00 | 104.00 | 123.00 | 59.00 | 109.00 | -- | 75.00 | 101.00 |
| Provision for income taxes | 804.00 | (2,691.00) | 612.00 | 1,285.00 | 1,318.00 | 1,130.00 | 1,637.00 | 2,679.00 | 1,995.00 | 1,982.00 |
| Deferred: Federal | 328.00 | (3,074.00) | (612.00) | (219.00) | (59.00) | (32.00) | -- | -- | (3.00) | (55.00) |
| Deferred: State | 1.00 | (504.00) | (76.00) | (25.00) | (20.00) | (26.00) | -- | -- | 9.00 | 6.00 |
| Currently payable: International | 583.00 | 679.00 | 621.00 | 597.00 | 633.00 | 673.00 | 763.00 | -- | 733.00 | 566.00 |
| Deferred: International | (27.00) | (246.00) | (2.00) | 72.00 | (79.00) | (78.00) | -- | -- | (11.00) | 26.00 |
| Minority interest | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Income (loss) from unconsolidated subsidiaries, net of taxes | 9.00 | 18.00 | 11.00 | 10.00 | (5.00) | -- | -- | -- | -- | -- |
| INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGE | 4,024.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income (loss) from discontinued operations, net of taxes | 164.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income including noncontrolling interest | 4,188.00 | (6,979.00) | 5,791.00 | 5,929.00 | 5,388.00 | 4,582.00 | 5,363.00 | 4,869.00 | 5,058.00 | 4,841.00 |
| Less- Net income attributable to noncontrolling interest | 15.00 | 16.00 | 14.00 | 8.00 | 4.00 | 12.00 | 14.00 | 11.00 | 8.00 | 8.00 |
| Net Income (Loss) Available to Common Shareholders | 4,173.00 | (6,995.00) | 5,777.00 | 5,921.00 | 5,384.00 | 4,570.00 | 5,349.00 | 4,858.00 | 5,050.00 | 4,833.00 |
| Basic: Income before cumulative effect of accounting change | 7.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings (loss) per share from Discontinued Operations - Basic | 0.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Basic: Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings per share - Basic | 7.58 | (12.63) | 10.21 | 10.23 | 9.32 | 7.92 | 9.09 | 8.13 | 8.35 | 7.72 |
| Diluted: Income before cumulative effect of accounting change | 7.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings (loss) per share from Discontinued operations - Diluted | 0.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diluted: Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings per share - Diluted | 7.55 | (12.63) | 10.18 | 10.12 | 9.25 | 7.81 | 8.89 | 7.93 | 8.16 | 7.58 |
| Weighted average common shares outstanding - Basic | 550.80 | 553.90 | 566.00 | 579.00 | 577.60 | 577.00 | 588.50 | 597.50 | 604.70 | 625.60 |
| Weighted average common shares outstanding - Diluted | 552.40 | 553.90 | 567.60 | 585.30 | 582.20 | 585.10 | 602.00 | 612.70 | 618.70 | 637.20 |